Fenfluramine approved for use in the EU for Dravet syndrome

The oral solution will specifically be licensed as an add-on therapy to other anti-epileptic medicines for patients two years of age and older. Approval is based on data from two phase III trials which found that fenfluramine reduced seizure frequency.

Source:

PharmaTimes